DSCR1 Use for DSCR1 in Down syndrome with intellectual disability

摘要

The present invention relates to the use of Down syndrome critical region 1 (DSCR1) in Down syndrome disease with intellectual disability, in particular, in hippocampal dentate gyrus where normalization of the amount of DSCR1 gene in Ts65Dn mice is impaired. Showed that it restored neuronal progenitor cell proliferation and affected hippocampus learning and memory. Therefore, the pharmacological approach strategy targeting the DSCR1 gene is expected to contribute to the treatment of intellectual disorders associated with Down syndrome.